Article Figures & Data
Tables
- Table 1
Clinical characteristics and chronic complications in T1D (n=412)
All patients
(n=412)Glargine U300 (n=187) Degludec
(n=225)P value Age (years) 37.0±13.4 37.7±14.1 36.6±12.8 0.376 Gender male 214 (52%) 111 (59.4%) 103 (45.8%) 0.004 Diabetes duration (years) 18.7±12.3 17.6±12.6 19.8±11.9 0.112 Weight (kg) 72.0±14.9 71.7±13.7 72.3±15.9 0.759 BMI (kg/m2) 25.3±4.6 25.1±4.5 25.4±4.8 0.551 HbA1c (%) 7.8±1.4 7.6±1.2 8.1±1.5 <0.001 Patients with HbA1c ≤7% 113 (27.4%) 65 (35.3%) 48 (21.5%) 0.001 Patients with HbA1c ≥8% 148 (35.9%) 53 (28.3%) 95 (42.2%) 0.003 Carbohydrate counting (%) 106 (25.7%) 47 (25.1%) 59 (26.2%) 0.458 Patients with FSL (%) 80 (19.0%) 27 (14.4%) 44 (19.6%) 0.107 Time in range 70–180 mg/dL (%) 47.3±18.0 51.1±14.6 45.0±19.5 0.183 Time in hypoglycemia <70 mg/dL (%) 6.8±6.6 9.2±8.3 5.8±4.4 0.053 Time in hyperglycemia >180 mg/dL (%) 46.5±19.9 39.6±16.4 50.5±20.7 0.023 Active smoking (%) 101 (24.5%) 44 (23.5%) 57 (25.3%) 0.379 Antihypertensive treatment (%) 78 (18.9%) 33 (17.6%) 45 (20.0%) 0.307 Lipid-lowering treatment (%) 147 (35.7%) 65 (34.7%) 82 (36.4%) 0.349 Diabetic retinopathy (%) 194 (47.0%) 79 (42.2%) 115 (51.1%) 0.056 DR mild-to-moderate 114 (27.6%) 43 (23.0%) 71 (31.5%) Laser therapy 53 (12.9%) 29 (15.5%) 24 (10.6%) Surgery 27 (6.6%) 7 (3.6%) 20 (8.9%) Diabetic nephropathy 52 (12.6%) 20 (10.7%) 32 (14.2%) 0.327 Albuminuria 42 (10.2%) 16 (8.6%) 26 (11.6%) Dialysis of kidney transplant 10 (2.4%) 4 (2.1%) 6 (2.7%) Macrovascular complications (%) 23 (5.6%) 9 (4.8%) 14 (6.2%) 0.089 BMI, body mass index; DR, diabetic retinopathy; FSL, freestyle libre; HbA1c, glycosylated hemoglobin; T1D, type 1 diabetes.
- Table 2
Non-insulin hypoglycemic agents and daily insulin doses requirements in T1D using glargine U300 or degludec (n=412)
All patients
(n=412)Glargine U300 (n=187) Degludec
(n=225)P value Non-insulin antidiabetics (%) 30 (7.3) 11 (5.9) 19 (8.4) 0.233 Basal insulin Unit/day 31.5±16.9 30.1±14.9 32.2±18.4 0.759 Unit/kg/day 0.43±0.20 0.43±0.19 0.44±0.21 0.563 Prandial insulin Unit/day 23.5±16.9 22.5±16.1 23.2±16.0 0.603 Unit/kg/day 0.33±0.23 0.32±0.23 0.33±0.20 0.851 Total insulin Unit/day 54.0±29.1 52.8±27.4 55.4±29.5 0.383 Unit/kg/day 0.77±0.36 0.76±0.35 0.76±0.33 0.683 Basal/Total insulin ratio 0.58±0.14 0.59±0.14 0.58±0.14 0.441 T1D, type 1 diabetes.
- Table 3
Daily insulin doses requirements by metabolic control subgroups in T1D using glargine U300 or degludec
HbA1c ≤7%
(IGla: 65 P; IDeg: 48 P)HbA1c 7.1%–8%
(IGla: 69 P; IDeg: 82 P)HbA1c ≥8%
(IGla: 53 P; IDeg: 95 P)P value P value P value Basal insulin Unit/day IGla-300 25.8±13.4 0.781 30.8±15.7 0.780 35.1±13.8 0.779 IDeg 26.6±16.8 31.6±19.0 35.8±18.1 Unit/kg/day IGla-300 0.36±0.16 0.558 0.43±0.17 0.870 0.51±0.18 0.643 IDeg 0.38±0.20 0.42±0.21 0.49±0.21 Prandial insulin Unit/day IGla-300 18.7±12.4 0.552 25.1±19.9 0.055 24.5±14.6 0.185 IDeg 20.0±9.8 19.7±11.1 28.4±20.2 Unit/kg/day IGla-300 0.26±0.17 0.404 0.35±0.27 0.070 0.37±0.21 0.451 IDeg 0.29±0.11 0.27±0.16 0.40±0.26 Total insulin Unit/day IGla-300 44.7±22.2 0.893 56.2±32.3 0.285 59.6±24.7 0.342 IDeg 45.3±24.1 51.0±25.1 64.3±33.2 Unit/kg/day IGla-300 0.64±0.29 0.857 0.79±0.37 0.135 0.88±0.34 0.782 IDeg 0.64±0.24 0.69±0.28 0.89±0.38 B/T ratio IGla-300 0.60±0.15 0.032 0.58±0.15 0.217 0.60±0.13 0.269 IDeg 0.55±0.11 0.61±0.14 0.57±0.15 B/T, basal/total insulin; HbA1c, glycosylated hemoglobin; IDeg, insulina degludec; IGla-300, insulina glargina 300 UI/mL; P, patients; T1D, type 1 diabetes.
Vol 69 Issue 5
Table of Contents
